The BRAF V600E mutation has been reported to be correlated with sensitivity to MEK inhibitors [8], [9] and has been used as a major criterion for recruiting patients into a clinical trial of MEK inhibitors in melanoma patients. This evidence concerns the gene MAP2K7 and melanoma.